1089 related articles for article (PubMed ID: 33197395)
1. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
Ponikowski P; Kirwan BA; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Göhring UM; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Butler J; Friede T; Jensen KH; Pocock S; Jankowska EA;
Lancet; 2020 Dec; 396(10266):1895-1904. PubMed ID: 33197395
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure.
Ponikowski P; Kirwan BA; Anker SD; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Haboubi T; Keren A; Khintibidze I; Kragten H; Martinez FA; McDonagh T; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Jankowska EA
Eur J Heart Fail; 2019 Dec; 21(12):1651-1658. PubMed ID: 31883356
[TBL] [Abstract][Full Text] [Related]
3. Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.
Filippatos G; Ponikowski P; Farmakis D; Anker SD; Butler J; Fabien V; Kirwan BA; Macdougall IC; Metra M; Rosano G; Ruschitzka F; van der Meer P; Wächter S; Jankowska EA;
Circulation; 2023 May; 147(22):1640-1653. PubMed ID: 37051919
[TBL] [Abstract][Full Text] [Related]
4. Ferric carboxymaltose in patients with heart failure and iron deficiency.
Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
[TBL] [Abstract][Full Text] [Related]
5. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.
Kalra PR; Cleland JGF; Petrie MC; Thomson EA; Kalra PA; Squire IB; Ahmed FZ; Al-Mohammad A; Cowburn PJ; Foley PWX; Graham FJ; Japp AG; Lane RE; Lang NN; Ludman AJ; Macdougall IC; Pellicori P; Ray R; Robertson M; Seed A; Ford I;
Lancet; 2022 Dec; 400(10369):2199-2209. PubMed ID: 36347265
[TBL] [Abstract][Full Text] [Related]
6. Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney Function.
Macdougall IC; Ponikowski P; Stack AG; Wheeler DC; Anker SD; Butler J; Filippatos G; Göhring UM; Kirwan BA; Kumpeson V; Metra M; Rosano G; Ruschitzka F; van der Meer P; Wächter S; Jankowska EA
Clin J Am Soc Nephrol; 2023 Sep; 18(9):1124-1134. PubMed ID: 37382961
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of intravenous ferric carboxymaltose compared with oral iron for the treatment of iron deficiency anaemia in women after childbirth in Tanzania: a parallel-group, open-label, randomised controlled phase 3 trial.
Vanobberghen F; Lweno O; Kuemmerle A; Mwebi KD; Asilia P; Issa A; Simon B; Mswata S; Schmidlin S; Glass TR; Abdulla S; Daubenberger C; Tanner M; Meyer-Monard S
Lancet Glob Health; 2021 Feb; 9(2):e189-e198. PubMed ID: 33245866
[TBL] [Abstract][Full Text] [Related]
8. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial.
Khalafallah AA; Yan C; Al-Badri R; Robinson E; Kirkby BE; Ingram E; Gray Z; Khelgi V; Robertson IK; Kirkby BP
Lancet Haematol; 2016 Sep; 3(9):e415-25. PubMed ID: 27570088
[TBL] [Abstract][Full Text] [Related]
9. Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design.
Mentz RJ; Ambrosy AP; Ezekowitz JA; Lewis GD; Butler J; Wong YW; De Pasquale CG; Troughton RW; O'Meara E; Rockhold FW; Garg J; Samsky MD; Leloudis D; Dugan M; Mundy LM; Hernandez AF;
Circ Heart Fail; 2021 May; 14(5):e008100. PubMed ID: 34003690
[TBL] [Abstract][Full Text] [Related]
10. Ferric Carboxymaltose in Heart Failure with Iron Deficiency.
Mentz RJ; Garg J; Rockhold FW; Butler J; De Pasquale CG; Ezekowitz JA; Lewis GD; O'Meara E; Ponikowski P; Troughton RW; Wong YW; She L; Harrington J; Adamczyk R; Blackman N; Hernandez AF;
N Engl J Med; 2023 Sep; 389(11):975-986. PubMed ID: 37632463
[TBL] [Abstract][Full Text] [Related]
11. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.
Anker SD; Kirwan BA; van Veldhuisen DJ; Filippatos G; Comin-Colet J; Ruschitzka F; Lüscher TF; Arutyunov GP; Motro M; Mori C; Roubert B; Pocock SJ; Ponikowski P
Eur J Heart Fail; 2018 Jan; 20(1):125-133. PubMed ID: 28436136
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design of the IRON-CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy.
Martens P; Dupont M; Dauw J; Somers F; Herbots L; Timmermans P; Verwerft J; Mullens W
ESC Heart Fail; 2019 Dec; 6(6):1208-1215. PubMed ID: 31562751
[TBL] [Abstract][Full Text] [Related]
13. Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial.
Metra M; Jankowska EA; Pagnesi M; Anker SD; Butler J; Dorigotti F; Fabien V; Filippatos G; Kirwan BA; Macdougall IC; Rosano G; Ruschitzka F; Tomasoni D; van der Meer P; Ponikowski P;
Eur J Heart Fail; 2022 Oct; 24(10):1928-1939. PubMed ID: 35869741
[TBL] [Abstract][Full Text] [Related]
14. Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF).
Yeo TJ; Yeo PSD; Hadi FA; Cushway T; Lee KY; Yin FF; Ching A; Li R; Loh SY; Lim SL; Wong RC; Tai BC; Richards AM; Lam CSP
ESC Heart Fail; 2018 Apr; 5(2):344-353. PubMed ID: 29345426
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.
Ponikowski P; van Veldhuisen DJ; Comin-Colet J; Ertl G; Komajda M; Mareev V; McDonagh T; Parkhomenko A; Tavazzi L; Levesque V; Mori C; Roubert B; Filippatos G; Ruschitzka F; Anker SD;
Eur Heart J; 2015 Mar; 36(11):657-68. PubMed ID: 25176939
[TBL] [Abstract][Full Text] [Related]
16. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
Lyseng-Williamson KA; Keating GM
Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
18. Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial.
Spahn DR; Schoenrath F; Spahn GH; Seifert B; Stein P; Theusinger OM; Kaserer A; Hegemann I; Hofmann A; Maisano F; Falk V
Lancet; 2019 Jun; 393(10187):2201-2212. PubMed ID: 31036337
[TBL] [Abstract][Full Text] [Related]
19. Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response Among Patients With Acute Isovolemic Anemia Following Gastrectomy: The FAIRY Randomized Clinical Trial.
Kim YW; Bae JM; Park YK; Yang HK; Yu W; Yook JH; Noh SH; Han M; Ryu KW; Sohn TS; Lee HJ; Kwon OK; Ryu SY; Lee JH; Kim S; Yoon HM; Eom BW; Choi MG; Kim BS; Jeong O; Suh YS; Yoo MW; Lee IS; Jung MR; An JY; Kim HI; Kim Y; Yang H; Nam BH;
JAMA; 2017 May; 317(20):2097-2104. PubMed ID: 28535237
[TBL] [Abstract][Full Text] [Related]
20. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.
Jankowska EA; Kirwan BA; Kosiborod M; Butler J; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Filippatos G; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Friede T; Fabien V; Dorigotti F; Pocock S; Ponikowski P
Eur Heart J; 2021 Aug; 42(31):3011-3020. PubMed ID: 34080008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
